1. Home
  2. REGCP vs PHVS Comparison

REGCP vs PHVS Comparison

Compare REGCP & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Regency Centers Corporation

REGCP

Regency Centers Corporation

N/A

Current Price

$23.27

Market Cap

0.0

Sector

N/A

ML Signal

N/A

Logo Pharvaris N.V.

PHVS

Pharvaris N.V.

HOLD

Current Price

$26.57

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
REGCP
PHVS
Founded
N/A
2015
Country
United States
Switzerland
Employees
500
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
N/A
1.7B
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
REGCP
PHVS
Price
$23.27
$26.57
Analyst Decision
Buy
Analyst Count
0
9
Target Price
N/A
$39.44
AVG Volume (30 Days)
N/A
469.3K
Earning Date
N/A
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
N/A
$11.51
52 Week High
N/A
$29.80

Technical Indicators

Market Signals
Indicator
REGCP
PHVS
Relative Strength Index (RSI) 44.40 54.30
Support Level $23.24 $25.27
Resistance Level $23.56 $26.09
Average True Range (ATR) 0.17 1.35
MACD -0.00 0.13
Stochastic Oscillator 51.46 59.75

Price Performance

Historical Comparison
REGCP
PHVS

About REGCP Regency Centers Corporation

Regency Centers is one of the largest shopping center-focused retail REITs. The company's portfolio includes an interest in 483 properties, which includes over 57 million square feet of retail space following the completion of the Urstadt Biddle acquisition in August 2023. The portfolio is geographically diversified with 22 regional offices and no single market representing more than 12% of total company net operating income. Regency's retail portfolio is primarily composed of grocery-anchored centers, with 80% of properties featuring a grocery anchor and grocery stores representing 20% of annual base rent.

About PHVS Pharvaris N.V.

Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.

Share on Social Networks: